Wall Street analysts forecast that Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 5.9%. It is ...

Angelini Pharma’s $4.1B buyout of Catalyst (CPRX) at $31.50/share offers a 28% premium and Q3 2026 close outlook—read the deal details now.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A. for $31.50 per share in cash.Halper Sadeh encourages Catalyst ...

CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces ...

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

What Is Multi-Timeframe Analysis? How to Align Weekly, Daily, and Hourly Charts Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022’s first outlier institutional inflow signal. CPRX ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

Catalyst Pharmaceuticals soared 19% after a report that Italian drugmaker Angelini Pharma is evaluating a potential purchase ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two ...